The natural¹ restoration solution your patients deserve

Fibrillar Type I and Type III Collagen in the Operating Room

There is always a risk of complications with surgical wounds, especially in patients that are deemed high risk because of certain well-documented comorbidities (obesity, diabetes, etc.).²

These complications include:

SURGICAL WOUND DEHISCENCE
NECROSIS
COMPROMISED WOUND HEALING

Surgeons may use NIVIS to jumpstart wound healing, control minor bleeding, and to help manage moderate to heavy exudating wounds.³

Support Your Surgical Procedures With A Focus On Value

NIVIS Fibrillar Collagen Pack is an absorbent collagen matrix of Type I and Type III bovine collagen designed to:

Closely resemble the body’s native collagen through a manufacturing process designed to maintain and preserve the collagen’s natural, triple helix structure.⁴
Help decrease product waste by providing different sizing options to encourage the right amount of product is being used at the right time.⁴
Be competitively priced without sacrificing collagen quality.⁴
Be highly absorbent for easier application and adherence to the wound site.⁴
Perform like native collagen which has been shown to stimulate cellular activity and contribute to new tissue development.⁵

Why NIVIS Fibrillar Collagen Pack?

The collagen in NIVIS serves as a scaffold that allows for cell adhesion and migration into the wound site and promotes wound healing. ⁶

Contains Type I and Type III collagen
Highly purified for biocompatibility⁴
100% resorbable through normal metabolic pathways⁷
Absorbancy allows for management of wound fluids while maintaining a moist environment for optimal healing⁷
Contains intrinsic hemostatic properties to control minor bleeding^7,8
Type III collagen controls wound contraction rate and amount of scar deposition during wound healing⁹
Type III collagen enables the proper fibrillogenesis of Type I collagen¹⁰

DID YOU KNOW?
Collagen is the single most abundant protein in the human body³

NIVIS Ordering Information

Product Number	Description	Size
FCWD05	NIVIS Fibrillar Collagen Pack	.5 g
FCWD10	NIVIS Fibrillar Collagen Pack	1.0 g
FCWD20	NIVIS Fibrillar Collagen Pack	2.0 g

References: 1. Mathew-Steiner, Shomita S et al. “Collagen in Wound Healing.” Bioengineering (Basel, Switzerland) vol. 8,5 63. 11 May. 2021, doi:10.3390/bioengineering8050063, 2. Shaydakov ME, Tuma F. Operative Risk. [Updated 2022 May 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https://www.ncbi.nlm.nih.gov/books/ NBK532240/, 3. Ehrlich H. P. (1988). Wound closure: evidence of cooperation between fibroblasts and collagen matrix. Eye (London, England), 2 ( Pt 2), 149–157. https://doi.org/10.1038/eye.1988.28, 4. Data on file, 5. Elango, Jeevithan et al. “The Molecular Interaction of Collagen with Cell Receptors for Biological Function.” Polymers vol. 14,5 876. 23 Feb. 2022, doi:10.3390/polym14050876, 6. Kallis, P. J., & Friedman, A. J. (2018). Collagen Powder in Wound Healing. Journal of drugs in dermatology : JDD, 17(4), 403–408., 7. Li ST. 2000. Biologic Biomaterials: Tissue-Derived Biomaterials (Collagen). Biomedical Engineering Handbook, Second Edition. Vol I, JD Bronzino (ed.), pp 42: 1-23, CRC Press, Boca Raton, FL., 8. Jaffe R., Deykin DJ. 1974. Evidence for a Structural Requirement for the Aggregation of Platelet by Collagen. CI in invest 53:875-88., 9. Ehrlich H. P. (1988). Wound closure: evidence of cooperation between fibroblasts and collagen matrix. Eye (London, England), 2 ( Pt 2), 149–157. https://doi.org/10.1038/eye.1988.28, 10. Liu, X., Wu, H., Byrne, M., Krane, S., & Jaenisch, R. (1997). Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proceedings of the National Academy of Sciences of the United States of America, 94(5), 1852–1856. https://doi.org/10.1073/ pnas.94.5.1852.

Intended Use: NIVIS Fibrillar Collagen Pack is indicated for the management of moderately to heavily exudating wounds and to control minor bleeding. NIVIS Fibrillar Collagen Pack may be used for the management of exudating wounds such as pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds, for example trauma and surgical wounds, and partial-thickness burns.

Caution: Federal (US) law restricts this device to sale by or on order of a physician.

Do not use NIVIS in patients known to be sensitive to materials of Bovine (cow) origin. Use of NIVIS in this patient population may result in an allergic or immunological reaction.

Some reactions such as transitory pain, bleeding, blistering, swelling and redness have been reported in isolated cases using a similar product. For additional important safety information, please see the NIVIS Instructions for Use.

Healthcare professionals must use their own clinical judgment in evaluating appropriate treatment options for a particular patient. Treatment of a specific patient should be based on individual needs and the medical care deemed necessary by the patient’s treating physician and institutional protocols. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your TELA Bio representative if you have questions about TELA Bio products.